MTOR and nonpapillary renal cell carcinoma: Preclinical models demonstrate the synergistic effects of sunitinib with mTOR inhibitors (temsirolimus) or epigenetic modulators, while ongoing clinical trials are investigating immune checkpoint inhibitors in refractory ccRCC [18–20].